ZA202310013B - Chelators for radiometals and methods of making and using same - Google Patents

Chelators for radiometals and methods of making and using same

Info

Publication number
ZA202310013B
ZA202310013B ZA2023/10013A ZA202310013A ZA202310013B ZA 202310013 B ZA202310013 B ZA 202310013B ZA 2023/10013 A ZA2023/10013 A ZA 2023/10013A ZA 202310013 A ZA202310013 A ZA 202310013A ZA 202310013 B ZA202310013 B ZA 202310013B
Authority
ZA
South Africa
Prior art keywords
making
methods
radiometals
chelators
same
Prior art date
Application number
ZA2023/10013A
Other languages
English (en)
Inventor
Luke Wharton
Chris Orvig
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of ZA202310013B publication Critical patent/ZA202310013B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA2023/10013A 2021-05-07 2023-10-26 Chelators for radiometals and methods of making and using same ZA202310013B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163185951P 2021-05-07 2021-05-07
PCT/CA2022/050712 WO2022232943A1 (en) 2021-05-07 2022-05-06 Chelators for radiometals and methods of making and using same

Publications (1)

Publication Number Publication Date
ZA202310013B true ZA202310013B (en) 2024-05-30

Family

ID=83931919

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/10013A ZA202310013B (en) 2021-05-07 2023-10-26 Chelators for radiometals and methods of making and using same

Country Status (7)

Country Link
US (1) US20240254085A1 (enExample)
EP (1) EP4334290A4 (enExample)
JP (1) JP2024517879A (enExample)
AU (1) AU2022271362A1 (enExample)
CA (1) CA3217801A1 (enExample)
WO (1) WO2022232943A1 (enExample)
ZA (1) ZA202310013B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024235273A1 (zh) * 2023-05-15 2024-11-21 成都社泰医疗科技有限公司 多靶向化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186328A1 (en) * 2019-03-20 2020-09-24 The University Of British Columbia Chelators and methods of making and using same

Also Published As

Publication number Publication date
US20240254085A1 (en) 2024-08-01
JP2024517879A (ja) 2024-04-23
WO2022232943A1 (en) 2022-11-10
CA3217801A1 (en) 2022-11-10
EP4334290A4 (en) 2026-01-28
EP4334290A1 (en) 2024-03-13
AU2022271362A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
PL1601384T3 (pl) Sposoby radiofluorowania biologicznie czynnych wektorów
MX2010002258A (es) Compuestos terapeuticos de isoxazol.
PH12022550124A1 (en) Enzyme inhibitors
AU2483000A (en) Treatment of asthma with mek inhibitors
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
NZ545935A (en) Method of treating cancer with HDAC inhibitors
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PA8539801A1 (es) Derivados del ácido isoftálico como inhibidores de metaloproteinasas de la matriz
NZ517616A (en) Use of retigabin for treating neuropathic pain
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20083207L (no) Inhibitorer av IAP
PH12021553233A1 (en) Imidazopyrimidines as eed inhibitors and the use thereof
SE0202539D0 (sv) Compounds
MXPA05005146A (es) Indolpiridinio sustituido como compuestos antiinfecciosos.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2022002069A (es) Inhibidores de enzimas.
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2024015922A (es) Degradadores de proteinas del factor 2 relacionado con el eritroide de factor nuclear 2 (nrf2)
MX2024006684A (es) Inhibidores de hdac novedosos y uso terapéutico de estos.
ZA202203360B (en) Peptide amide composition and preparation method therefor
IL173377A0 (en) Compounds for the treatment of metabolic disorders
NZ547795A (en) 3-Cyano-quinoline derivatives with antiproliferative activity
SI1511472T1 (sl) Spojine uporabne pri zdravljenju antraksa in inhibiranju letalnega faktorja
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.